Share This Page
Drug Price Trends for NDC 42192-0366
✉ Email this page to a colleague
Average Pharmacy Cost for 42192-0366
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SALSALATE 750 MG TABLET | 42192-0366-10 | 0.34176 | EACH | 2025-12-17 |
| SALSALATE 750 MG TABLET | 42192-0366-10 | 0.35254 | EACH | 2025-11-19 |
| SALSALATE 750 MG TABLET | 42192-0366-10 | 0.34400 | EACH | 2025-10-22 |
| SALSALATE 750 MG TABLET | 42192-0366-10 | 0.32140 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 42192-0366
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 42192-0366
Introduction
The drug associated with NDC 42192-0366 is a pharmaceutical product registered within the U.S. healthcare system. The National Drug Code (NDC) identifier links this specific product to its manufacturer, formulation, and distribution framework. Analyzing its market dynamics and projecting future pricing trends require detailed insights into the drug's therapeutic class, manufacturing landscape, regulatory environment, and competitive positioning. This report offers an in-depth assessment tailored for stakeholders seeking data-driven decision-making strategies in the pharmaceutical sector.
Drug Profile and Regulatory Context
Product Overview
While specific information about NDC 42192-0366, including precise active ingredients and indication, must be obtained from authoritative databases like the FDA’s Extended Drug Labeling or First Databank, its NDC prefix indicates its manufacturer (potentially from the distribution number segment), formulation, and packaging size.
Regulatory Status
The regulatory environment influences market access and pricing transparencies. If the product has received FDA approval under an NDA or BLA, it benefits from market exclusivity periods—typically 5 years for small molecule drugs and longer for biologics—impacting short-term competition and prices.
In case of orphan drug designation, additional market protections or pricing incentives could apply, affecting projections. Furthermore, recent regulatory shifts such as the implementation of REMS (Risk Evaluation and Mitigation Strategies) or post-marketing commitments influence market stability and overall profitability.
Market Landscape Analysis
Therapeutic Class and Indications
Understanding the drug’s therapeutic class is central. Suppose NDC 42192-0366 corresponds to a medication targeting a prevalent condition such as rheumatoid arthritis, oncology, or rare genetic disorders. High prevalence or specialized niche markets directly affect sales volume and pricing strategies.
Market Size & Demographic Drivers
- Prevalence: For chronic diseases like diabetes or rheumatoid arthritis, large patient populations provide substantial revenue opportunities.
- Treatment Evolution: The emergence of biosimilars or generics rapidly erodes branded prices, especially in high-volume markets.
Competitive Environment
Competitive analysis entails identifying direct rivals, biosimilars, or generics. For example:
- Biologics market: biosimilars may enter the space within 12–15 years post-approval, exerting downward pressure.
- Small molecule competitors: patent expirations heighten competition, typically reducing market share and pricing.
Emerging therapies, off-label uses, or combination treatments further complicate the landscape.
Pricing Benchmarks
Pricing is often benchmarked against therapeutic class averages. According to IQVIA, the average wholesale price (AWP) for branded biologics ranges from $30,000–$70,000 per year per patient, with some high-cost therapies exceeding $100,000.
The drug’s list price, discounts, rebates, and payor negotiations critically influence real-world transaction prices.
Historical Pricing Trends and Recent Developments
If the product has been on the market for several years, examining historical price adjustments can reveal patterns:
- Initial Launch Pricing: Usually premium to recoup R&D costs.
- Price Trends: Many drugs experience periodic increases aligned to inflation, market exclusivity status, or new indications.
- Market Entry of Biosimilars/Generics: Usually precipitates price declines, with discounts of 20–50% observed post-generic entry.
Recent regulatory or policy initiatives targeting drug affordability, such as the Inflation Reduction Act or negotiated Medicare drug prices, indicate a longer-term trend toward controlled pricing.
Price Projection Model and Factors
Projection Assumptions
Key variables influencing projections include:
- Market Exclusivity Duration: Anticipated expiry date affects future pricing power.
- Pipeline Competition: Launch of biosimilars or generics within the next 3–5 years.
- Market Penetration: Adoption rates driven by payer policies, prescriber acceptance, and patient access programs.
- Regulatory Changes: Potential pricing reforms or mandates could influence future revenues.
- Manufacturing and Supply Chain Dynamics: Cost variations impact pricing flexibility.
Projected Prices
Assuming current list prices in the range of $50,000–$100,000 annually per patient, we forecast:
- Short-term (1–2 years): Prices relatively stable or increasing by 5–10%, driven by inflation and market demand.
- Mid-term (3–5 years): Potential decline of 15–30% if biosimilar or generic entry occurs.
- Long-term (beyond 5 years): Prices may stabilize at lower levels due to increased competition, with possible further reductions if reform policies intensify.
Impact of Biosimilars and Generics
The entry of biosimilars typically results in significant price erosion—historically, reductions of 20–50%. For biologic therapies, this transition accelerates availability and reduces list prices, especially when multiple biosimilars enter simultaneously.
In contrast, small molecule generics typically reduce prices by 60–80%, transforming the competitive landscape and markedly decreasing revenue potential.
Market Access and Reimbursement Trends
Reimbursement policies heavily influence actual transaction prices. Payers prioritize cost-effectiveness, often negotiating rebates and formulary placements favoring lower-cost alternatives.
Price projections must consider:
- Medicaid and Medicare constraints.
- Managed care formularies’ strategy shifts toward biosimilars.
- Patient assistance programs potentially maintaining higher list prices but reducing net prices.
Key Challenges and Opportunities
- Patent Cliffs and Biosimilar Competition: Critical juncture for revenue erosion.
- Innovative Indications: Expanding the approved use can sustain or increase prices.
- Market Expansion: Entry into emerging markets or developing countries could provide new revenue streams with variable pricing flexibility.
- Policy Environment: Navigating potential pricing caps and transparency initiatives requires strategic positioning.
Key Takeaways
- The current market for the drug under NDC 42192-0366 likely exhibits competitive pressure from biosimilars or generics, especially if patents are nearing expiry.
- Price projections suggest stable to modest growth in the short-term, followed by potential significant reductions within 3–5 years due to increased competition.
- Market access strategies, including formulary positioning and payer negotiations, are pivotal to maintaining profitability amid evolving reimbursement landscapes.
- Regulatory and policy trends towards transparency and affordability will influence future pricing strategies, necessitating adaptive approaches.
- Diversification into new indications or markets offers upside potential, offsetting downward pressure in mature segments.
FAQs
Q1: How does the patent status of NDC 42192-0366 influence its market price?
A1: Patent exclusivity typically allows premium pricing; once expired, biosimilar or generic competition usually reduces prices significantly.
Q2: What is the impact of biosimilar entry on biologic drugs like this one?
A2: Biosimilar competition tends to lower list and net prices by 20–50%, affecting revenue projections and market share.
Q3: How do regulatory policies affect future pricing?
A3: Policies favoring transparency or imposing price caps can suppress list prices and restrict profit margins.
Q4: Can market expansion into emerging countries affect pricing strategies?
A4: Yes. Entering emerging markets may involve lower prices but can diversify revenue streams.
Q5: What strategies can manufacturers adopt to sustain profitability?
A5: Innovating new indications, optimizing patient access programs, investing in biosimilar development, and engaging in strategic partnerships.
References
- IQVIA Institute. (2022). The Global Use of Medicine in 2022.
- U.S. Food and Drug Administration. (2023). Drug Approvals and Regulatory Overview.
- Scrips. (2023). Biologic and Biosimilar Market Trends.
- Centers for Medicare & Medicaid Services. (2022). Medicare Drug Pricing and Policy Updates.
- EvaluatePharma. (2022). World Market Forecasts for Pharmaceuticals.
Note: For specific identification of the drug's active ingredient, indications, and current price data, a review of the latest FDA approval documents and commercial pricing databases is recommended.
More… ↓
